January 21, 2021
Merck introduces 5-in-1 intranasal vaccine for cattle pneumonia
Merck Animal Health has announced that Bovilis® Nasalgen® 3-PMH is now available to veterinarians and cattle producers to protect cattle from five of the most common pneumonia-causing viral and bacterial pathogens, Hoard's Dairyman reported.
Approved for use in dairy and beef cattle, this is the first intranasal vaccine effective in providing early, broad-spectrum respiratory protection against both viral and bacterial pathogens in a needle free, animal- and BQA-friendly administration. Beef Quality Assurance (BQA) is a national programme that raises consumer confidence through offering proper management techniques and a commitment to quality within every segment of the beef industry.
"Bovilis Nasalgen 3-PMH is a modified-live, intranasal vaccine that stimulates a strong early immune response to help give calves a strong foundation of respiratory disease protection," says Scott Nordstrom, D.V.M., director of livestock innovation and discovery, Merck Animal Health. "Results of efficacy, duration of immunity and safety studies demonstrate the vaccine is safe and effective for calves at one week of age or older."
The vaccine protects against infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), parainfluenza 3 (PI3), Mannheimia haemolytica and Pasteurella multocida.
The vaccine is administered in a single 2-mL dose, and is available in 2-mL, 20-mL and 100-mL packages. It contains a unique BluShadowTM diluent that clearly indicates which animals have been vaccinated. With needle-free intranasal administration, the vaccine meets best management practices outlined in the industry's BQA programme.
